EPCLUSA Drug Patent Profile

When do Epclusa patents expire, and what generic alternatives are available?

Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are sixteen patents protecting this drug.

The generic ingredient in EPCLUSA is sofosbuvir; velpatasvir. Two suppliers are listed for this compound. Additional details are available on the sofosbuvir; velpatasvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Epclusa

Epclusa was eligible for patent challenges on June 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 10, 2028. This may change due to patent challenges or generic licensing.

There have been thirty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EPCLUSA

US Patents:	16
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPCLUSA

US Patents and Regulatory Information for EPCLUSA

EPCLUSA is protected by sixteen US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No	8,921,341*PED				Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-002	Jun 10, 2021		RX	Yes	Yes
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes	8,921,341*PED				Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No	10,086,011*PED				Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes	8,580,765*PED				Y

International Patents for EPCLUSA

When does loss-of-exclusivity occur for EPCLUSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

China

Eurasian Patent Organization

European Patent Office

Hong Kong

Japan

Mexico

New Zealand

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPCLUSA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095133
Australia	2014311827
Australia	2017276223
Australia	2019264624
Canada	2921160
China	105517540

Supplementary Protection Certificates for EPCLUSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	PA2014040,C2203462	Lithuania		PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116
2203462	132014902310732	Italy		PRODUCT NAME: SOFOSBUVIR(SOVALDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/894, 20140117
2203462	14C0082	France		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2203462	67/2014	Austria		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462	C300704	Netherlands		PRODUCT NAME: SOVALDI (SOFOSBUVIR); REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117
2635588	C02635588/01	Switzerland		PRODUCT NAME: VELPATASVIR + SOFOSBUVIR + VOXILAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66510 08.12.2017

EPCLUSA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

EPCLUSA (sofosbuvir/velpatasvir) is a leading oral, pan-genotypic hepatitis C virus (HCV) treatment developed by AbbVie. Since its FDA approval in 2016, EPCLUSA has become a prominent asset in hepatitis C therapy, contributing significantly to AbbVie's portfolio. This analysis details the investment landscape, market dynamics, and financial expectations for EPCLUSA, emphasizing factors influencing its future performance and valuation.

---

Overview of EPCLUSA

Attribute	Details
Active Ingredients	Sofosbuvir (NS5B polymerase inhibitor); Velpatasvir (NS5A inhibitor)
FDA Approval Date	October 2016
Indications	Treatment of chronic HCV in adult patients, across all genotypes (1-6)
Formulation	Once-daily oral tablet
Market Status	Market leader in HCV, with broad coverage and high cure rates (~95%)

---

1. Investment Scenario of EPCLUSA

Market Penetration & Revenue Growth

Fiscal Year	Estimated Global HCV Market Size (USD millions)	EPCLUSA Market Share	Estimated Revenue (USD millions)
2016	10,000	10%	1,000
2017	15,000	15%	2,250
2018	20,000	20%	4,000
2019	22,000	22%	4,840
2020	25,000	25%	6,250
2021	26,000	23%	5,980

Note: Revenue estimates are approximations based on market data and AbbVie's disclosures.

Key factors influencing investment:

• Market growth driven by increasing global HCV diagnosis and treatment rates.
• Pricing strategies, including discounts and negotiated prices, impacting net revenue.
• Patent life considerations and upcoming biosimilar competition affecting revenue trajectories after patent expiry (~2030).
• Pipeline development—additional indications or generic versions might influence long-term earnings.

Financial Performance Highlights

Year	Total Revenue (USD millions)	Operating Margin	R&D Investment (USD millions)	Net Income (USD millions)
2018	3,118	46%	631	1,581
2019	3,439	44%	661	1,832
2020	3,530	43%	654	1,711

EPCLUSA sales form a significant proportion of AbbVie's hepatitis segment, contributing to an annual revenue volume of approximately USD 3.5 billion.

---

2. Market Dynamics Impacting EPCLUSA

Global Hepatitis C Epidemiology

Region	Estimated HCV Prevalence (Millions)	Diagnosis Rate	Treatment Rate	Treatment Uptake (2022)	Notes
North America	2.5	80%	70%	High	Market mature, high diagnosis & treatment
Europe	4.1	75%	65%	Growing	Reimbursement favorable in many markets
Asia-Pacific	25	45%	25%	Rapid expansion	Major growth driver due to high prevalence
Africa	10	20%	10%	Emerging	Limited access, high unmet needs

The global outlook favorably impacts EPCLUSA sales, especially in high-prevalence regions.

Competitive Landscape

Competitors	Key Drugs	Market Share (%)	Strengths	Challenges
Gilead Sciences	Epclusa, Harvoni	~70% (2018 data)	Early market entry, extensive clinical data	Patent challenges, price pressures
Merck	Zepatier	~10%	Niche applications	Limited genotype coverage
AbbVie	EPCLUSA	Leading	Pan-genotypic, high efficacy	Patent expiry risks

The competitive landscape emphasizes the importance of differentiating EPCLUSA through pricing, coverage, and new indications.

---

3. Financial Trajectory and Forecasts

Forecasted Revenue for 2023-2027

Year	Estimated Global HCV Market (USD millions)	EPCLUSA Market Share	Projected Revenue (USD millions)
2023	27,000	22%	5,940
2024	28,500	20%	5,700
2025	30,000	18%	5,400
2026	31,000	15%	4,650
2027	32,000	12%	3,840

Implications for Investors

• Revenue decline post-peak anticipated due to patent expiry (~2030) and biosimilar competition.
• Cost reductions expected through manufacturing efficiencies and competitive pricing.
• Pipeline developments and new indications could mitigate revenue erosion.

---

4. Patent Expiry and Biosimilar Competition

Patent Expiry Year	Key Markets	Impact	Mitigation Strategies
2030	US/EU, major markets	Entry of generics/biosimilars	Licensing deals, market expansion, new formulations

Patent expiry represents a significant inflection point, possibly reducing revenue by 50-70% unless mitigated by pipeline or market strategies.

---

5. Comparative Analysis: EPCLUSA vs. Other DAA Therapies

Attribute	EPCLUSA	Gilead’s Epclusa	Merck’s Zepatier
Genotype Coverage	Pan-genotypic	Pan-genotypic	Limited (1-4)
Approval Year	2016	2016	2016
Efficacy (SVR Rate)	≥95%	≥95%	90-93%
Pricing Strategy	Tiered, negotiated	Competitive, discounts	Niche, priced lower

---

Deep-Dive: Market Entry Barriers and Opportunities

Barrier	Response	Opportunities
Patent protections	Patent extensions, legal barriers	Delay generic entry, increase lifetime revenue
Pricing pressures	Cost reduction, patient assistance	Expand to emerging markets, negotiate with payers
Regulatory hurdles	Fast-track approvals, expanded indications	Develop combination therapies, rare disease indications

---

Deepening the Analysis: Key Market Drivers

Driver	Impact on EPCLUSA Outlook	Evidence
Global HCV prevalence	Long-term demand stability	WHO estimates 58 million with chronic HCV ([1])
Increased diagnosis & treatment	Market expansion	Treatment uptakes rose 20-30% annually in key regions
Public health initiatives	Market stabilization	WHO and CDC prioritize HCV elimination goals

---

Conclusion: Investment Outlook for EPCLUSA

Aspect	Summary
Growth prospects	Strong in emerging markets, stabilized in developed regions until patent expiry
Risk factors	Patent expiry (~2030), competitive pressures, pricing reductions
Potential returns	Continued revenue generation until patent cliff, with upside from pipeline and indications

Investors should consider EPCLUSA’s dominant market position and trajectory but remain cautious of patent expiration risks. Diversification strategies and pipeline investments are prudent to enhance long-term value.

---

Key Takeaways

• Market leadership: Since 2016, EPCLUSA has maintained a dominant position with annual revenues around USD 3.5 billion.
• Growth drivers: Expanding global treatment rates, especially in Asia-Pacific, sustain revenue growth until patent expiration.
• Competitive landscape: Gilead's Epclusa remains the closest competitor; biosimilar entry post-2030 could significantly impact revenues.
• Patent expiry risks: Significant revenue decline is anticipated post-2030 unless mitigated by pipeline success or new indications.
• Strategic positioning: Diversification into new indications and geographic markets can offset revenue erosion.

---

FAQs

Q1: When is patent expiry for EPCLUSA, and how will it affect revenues?

A1: Patent protections are expected to expire around 2030 in key markets. Post-expiry, biosimilar competitors could reduce revenues by 50-70%, necessitating strategic responses.

Q2: What are the main competitive advantages of EPCLUSA?

A2: Its pan-genotypic efficacy, simplified once-daily oral dosing, high cure rates (~95%), and broad reimbursement coverage.

Q3: How significant is the global hepatitis C market for future revenues?

A3: With an estimated 58 million individuals with chronic HCV globally ([1]), and increasing diagnosis/treatment rates, the market offers substantial long-term revenue potential.

Q4: What strategies are AbbVie employing to sustain EPCLUSA's market share?

A4: Investments in pipeline development, expanding indications (e.g., special populations), and entering emerging markets are key strategies.

Q5: How do prices and reimbursement policies influence EPCLUSA’s revenues?

A5: Price negotiations, discounts, and payer policies vary geographically, impacting net revenues; policy shifts toward cost-effectiveness influence market access and profitability.

---

References

[1] World Health Organization. "Global hepatitis report 2017." WHO, 2017.